Sichenzia Ross Ference LLP Represents Inmune Bio, Inc. in a $40.0 Million Registered Direct Offering
Press Release – New York, New York – July 16, 2021 – Sichenzia Ross Ference LLP announced today that it represented Inmune Bio, Inc. (Nasdaq: INMB), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, in a registered direct offering of common stock at a purchase price of $22.00 per share with two institutional investor. The gross proceeds from the offering were $40.0 million.
A.G.P./Alliance Global Partners acted as sole placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Marc Ross, Thomas Rose and Barrett DiPaolo.
- Sichenzia Ross Ference LLP Represents ThinkEquity LLC in $6.87 Million Public Offering of Common Stock of Twin Vee PowerCats Co. - October 4, 2022
- Sichenzia Ross Ference LLP Represents Laidlaw & Company (UK) Ltd. in $5.75 Million Public Offering and Nasdaq Uplisting of Silo Pharma, Inc. - October 1, 2022
- Mid-Level Corporate Associate - September 29, 2022